Radioactive drug shows promise for tough prostate cancer

NCT ID NCT05670106

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a radioactive drug called 177Lu-PSMA-617 in 62 Chinese men with advanced prostate cancer that had spread and stopped responding to hormone therapy and chemotherapy. The drug targets a protein on cancer cells and delivers radiation directly to them. Researchers measured how well it shrank tumors and how safe it was, aiming to support approval in China.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-PSMA-617 (a radioactive drug that targets prostate cancer cells)
What this could lead to: If successful, this could provide a new treatment option for Chinese men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is a phase 2 study with only 62 participants, so results may not apply to all patients. The drug involves radiation, which can cause side effects like dry mouth, fatigue, and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Contacts and locations

Locations

Novartis Investigative Site

Guangzhou, Guangdong, 510120, China
Novartis Investigative Site

Zhengzhou, Henan, 450003, China
Novartis Investigative Site

Zhengzhou, Henan, 450008, China
Novartis Investigative Site

Wuhan, Hubei, 430022, China
Novartis Investigative Site

Nanjing, Jiangsu, 210006, China
Novartis Investigative Site

Nanjing, Jiangsu, 210029, China
Novartis Investigative Site

Xian, Shanxi, 710032, China
Novartis Investigative Site

Xian, Shanxi, 710061, China
Novartis Investigative Site

Chengdu, Sichuan, 610041, China
Novartis Investigative Site

Beijing, 100034, China
Novartis Investigative Site

Beijing, 100036, China
Novartis Investigative Site

Beijing, 100730, China
Novartis Investigative Site

Guangzhou, 510060, China
Novartis Investigative Site

Shanghai, 200025, China
Novartis Investigative Site

Shanghai, 200032, China
Novartis Investigative Site

Shanghai, 200080, China
Novartis Investigative Site

Tianjin, 300300, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.